THANK YOU FOR SUBSCRIBING
The partnership takes a pioneering approach to incorporating advanced colorectal cancer detection into the country's healthcare system.
FREMONT, CA: "TomaLab is the ideal partner to bring our pioneering product to Italy, given its state-of-the-art facilities and commitment to innovative healthcare solutions. This collaboration aligns with our mission to make advanced diagnostic tools widely accessible, improving early detection rates and ultimately saving lives," says Guido Baechler, CEO of Mainz Biomed.
Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, unveiled a strategic partnership with TomaLab to unveil the Company's flagship product, ColoAlert®, in Italy. TomaLab is a leading biotechnology laboratory in Italy, headquartered in Milan. The collaboration defines a significant step forward in improving colorectal cancer screening and diagnostics within the Italian healthcare system by allowing the integration of ColoAlert® into Italy's robust healthcare framework, giving patients access to a cutting-edge diagnostic solution that combines convenience and clinical excellence.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures. This partnership underlines our dedication to embracing cutting-edge technologies that enhance patient care and outcomes," says Dr. Riccardo Manca, CEO of TomaLab.
ColoAlert®, a highly effective and user-friendly at-home detection test, provides a non-invasive, highly sensitive method for detecting colorectal cancer (CRC) and precancerous lesions. ColoAlert® uses advanced DNA technology to see cancerous and precancerous conditions with greater precision than traditional non-invasive screening methods, making it an important tool in the fight against one of the world's most common and deadly cancers.
The unveiling of ColoAlert® in Italy comes at a critical time, as colorectal cancer is the country's second most common cancer. There is a worrying trend of increasing incidence rates among young adults. Early detection remains critical to rising survival rates, and with ColoAlert®'s advanced diagnostic capabilities, more people will have timely access to life-saving screenings.
More in News